LCDActive
Lab: Flow Cytometry
L34513
Effective: August 10, 2023
Updated: December 31, 2025
Policy Summary
Flow cytometry is covered for diagnostic and monitoring indications across hematolymphoid disorders (eg, leukemias, lymphomas, CLL, plasma cell disorders, MDS, CMPD), PNH, MRD detection, HIV T‑cell enumeration, transplant monitoring, select carcinoma DNA analyses, molar pregnancy evaluation, primary immunodeficiencies, platelet disorders, and non-neoplastic red/white cell disorders when clinically indicated. Panels generally should not exceed 24 markers; any markers beyond 24 require specific, documented justification in the FCM report or claims will be denied.
Coverage Criteria Preview
Key requirements from the full policy
"Flow cytometry (FCM) is indicated to evaluate single-cell characteristics from peripheral blood, body fluids, cerebrospinal fluid, bone marrow, lymph node, tonsil, spleen, and other solid tissues."
Sign up to see full coverage criteria, indications, and limitations.